Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Baseline gene expression predicts TKI response in CML

Key clinical point: Baseline gene expression predicted tyrosine kinase inhibitor 5-year responder status in chronic myeloid leukemia patients.

Major finding: A gene-expression model predicted 5-year responder status (area under the curve, 0.76).

Study details: A exploratory analysis of 70 patient samples from the ENESTnd trial.

Disclosures: The study was sponsored by Novartis. Dr. Radich is a paid consultant for Genentech, Cepheid, Bristol-Myers Squibb, Takeda, and Novartis.


Radich JP et al. SOHO 2020, Abstract CML-109.